MedTrace Logo

Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer

NCT00006269 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2012-05-25

No results posted yet for this study

Summary

RATIONALE: Octreotide may be effective in preventing diarrhea that is caused by treatment with irinotecan.

PURPOSE: Randomized phase III trial to study the effectiveness of octreotide in preventing diarrhea in patients who are receiving irinotecan for metastatic colon cancer.

Conditions

Interventions

DRUG

irinotecan hydrochloride

DRUG

octreotide acetate

Sponsors & Collaborators

Principal Investigators

  • Kurt Sizer, MD · Novartis Pharmaceuticals

Study Design

Purpose
SUPPORTIVE_CARE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-12-31
Primary Completion
1999-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006269 on ClinicalTrials.gov